Risk factors for excess mortality and death in adults with tuberculosis in Western Kenya

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 12, 2012, Pages 1649-1656

  Van't Hoog, A H ^a,b   Williamson, J ^a   Sewe, M ^a   Mboya, P ^c   Odeny, L O ^a   Agaya, J A ^a   Amolloh, M ^a   Borgdorff, M W ^b,d   Laserson, K F ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c MINISTRY OF HEALTH   (Kenya)

^d DEPARTMENT OF INFECTIOUS DISEASES   (Netherlands)

Author keywords

Excess mortality; HIV; Kenya; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; DISEASE ASSOCIATION; FEMALE; HEALTH SURVEY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SEX DIFFERENCE; STANDARDIZED MORTALITY RATIO; SURVIVAL; TREATMENT DURATION; TUBERCULOSIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-RETROVIRAL AGENTS; ANTITUBERCULAR AGENTS; CAUSE OF DEATH; COINFECTION; FEMALE; HIV INFECTIONS; HUMANS; KENYA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREVALENCE; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEX FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS; YOUNG ADULT;

EID: 84865724939     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0135     Document Type: Article

References (35)

1. Lopez A D, Mathers C D, Ezzati M, Jamison D T, Murray C J. Global burden of disease and risk factors. Washington DC, USA: World Bank, 2006.
2. Dye C, Maher D, Weil D, Espinal M, Raviglione M. Targets for global tuberculosis control. Int J Tuberc Lung Dis 2006; 10: 460-462.
3. United Nations. Millennium Development Goals. New York, NY, USA: UN, 2000. http://www.un.org/millenniumgoals/ Accessed August 2012.
4. World Health Organization. Global tuberculosis control. WHO report 2010. WHO/HTM/TB/2010.7 Geneva, Switzerland: WHO, 2010.
5. Mukadi Y D, Maher D, Harries A. Tuberculosis case fatality rates in high HIV prevalence populations in sub-Saharan Africa. AIDS 2001; 15: 143-152.
6. Straetemans M, Bierrenbach A L, Nagelkerke N, Glaziou P, van der Werf M J. The effect of tuberculosis on mortality in HIV positive people: a meta-analysis. PLoS ONE 2010; 5: e15241.
7. Waitt C J, Squire S B. A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis 2011; 15: 871-885.
8. World Health Organization Stop TB Partnership. The Stop TB strategy; building on and enhancing DOTS to meet the TBrelated Millennium Development Goals. WHO/HTM/TB/2006. 368. Geneva, Switzerland: WHO, 2006.
9. World Health Organization. Interim policy on collaborative TB/HIV activities. Geneva, Switzerland: WHO, Stop TB Department and Department of HIV/AIDS, 2004.
10. Korenromp E L, Bierrenbach A L, Williams B G, Dye C. The measurement and estimation of tuberculosis mortality. Int J Tuberc Lung Dis 2009; 13: 283-303.
11. Dye C, Bassili A, Bierrenbach A L, et al. Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect Dis 2008; 8: 233-243.
12. Straetemans M, Glaziou P, Bierrenbach A L, Sismanidis C, van der Werf M J. Assessing tuberculosis case fatality ratio: a metaanalysis. PLoS ONE 2011; 6: e20755.
13. van't Hoog A H, Laserson K F, Githui W A, et al. High prevalence of pulmonary tuberculosis and inadequate case finding in rural Western Kenya. Am J Respir Crit Care Med 2011; 183: 1245-1253.
14. National AIDS/STI Control Programme (NASCOP) Kenya. 2007 Kenya AIDS Indicator Survey: final report. Nairobi: NASCOP, 2009.
15. Adazu K, Lindblade K A, Rosen D H, et al. Health and demographic surveillance in rural Western Kenya: a platform for evaluating interventions to reduce morbidity and mortality from infectious diseases. Am J Trop Med Hyg 2005; 73: 1151-1158.
16. Kenya Ministry of Public Health and Sanitation, Division of Leprosy Tuberculosis and Lung Disease. Annual report. Nairobi, Kenya: Kenya Ministry of Public Health and Sanitation, 2007.
17. van't Hoog A H, Onyango J, Agaya J, et al. Evaluation of TB and HIV services prior to introducing TB-HIV activities in two rural districts in Western Kenya. Int J Tuberc Lung Dis 2008; 12 (Suppl 1): S32-S38.
18. Gargano J W, Laserson K, Muttai H, et al. The adult population impact of HIV care and antiretroviral therapy (ART), Nyanza Province, Kenya, 2003-2008. AIDS 2012; 26: 1545-1554.
19. Kenya Medical Research Institute/Centers for Disease Control and Prevention (CDC) Research and Public Health Collaboration. KEMRI/CDC Health and Demographic Surveillance System (HDSS). 6th Annual report. Kisumu, Kenya: KEMRI/CDC, 2008.
20. Amolloh M, Medley A, Owuor P, et al. Factors associated with early uptake of HIV care and treatment services after testing HIV-positive during home-based testing and counseling in rural Western Kenya. Boston, MA, USA: 18th Conference on Retroviruses and Opportunistic Infections, 27 February-2 March 2011. [Paper #1077]. http://www.retroconference.org/2011/Abstracts/40387.htm Accessed September 2012.
21. Lighter J, Rigaud M. Diagnosing childhood tuberculosis: traditional and innovative modalities. Curr Probl Pediatr Adolesc Health Care 2009; 39: 61-88.
22. Measure DHS. Methodology of DHS Mortality Rates Estimation DHS Statistics Live. Calverton, MD, USA: Measure DHS, 2006.
23. Dickman P W, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004; 23: 51-64.
24. Dickman P W. Estimating and modelling relative survival using SAS. Stockholm, Sweden: paudickman.com, 2004. http://www.pauldickman.com/rsmodel/ Accessed September 2012.
25. Au-Yeung C, Kanters S, Ding E, et al. Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment. Clin Epidemiol 2011; 3: 21-29.
26. Borgdorff M W, Veen J, Kalisvaart N A, Nagelkerke N. Mortality among tuberculosis patients in the Netherlands in the period 1993-1995. Eur Respir J 1998; 11: 816-820.
27. Harries A D, Zachariah R, Corbett E L, et al. The HIV-associated tuberculosis epidemic - when will we act? Lancet 2010; 375: 1906-1919.
28. Abdool Karim S S, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362: 697-706.
29. McIlleron H, Meintjes G, Burman W J, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 2007; 196 (Suppl 1): S63-S75.
30. Breen R A, Smith C J, Cropley I, Johnson M A, Lipman M C. Does immune reconstitution syndrome promote active tuberculosis in patients receiving highly active antiretroviral therapy? AIDS 2005; 19: 1201-1206.
31. Zachariah R, Teck R, Ascurra O, et al. Can we get more HIV-positive tuberculosis patients on antiretroviral treatment in a rural district of Malawi? Int J Tuberc Lung Dis 2005; 9: 238-247.
32. Vree M, Huong N T, Duong B D, et al. Mortality and failure among tuberculosis patients who did not complete treatment in Vietnam: a cohort study. BMC Public Health 2007; 7: 134.
33. Hargreaves N J, Kadzakumanja O, Phiri S, et al. What causes smear-negative pulmonary tuberculosis in Malawi, an area of high HIV seroprevalence? Int J Tuberc Lung Dis 2001; 5: 113-122.
34. Cain K P, Anekthananon T, Burapat C, et al. Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis 2009; 15: 258-264.
35. Nadol P, Stinson K W, Coggin W, et al. Electronic tuberculosis surveillance systems: a tool for managing today's TB programs. Int J Tuberc Lung Dis 2008; 12 (Suppl 1): S8-S16.